Provided by Tiger Trade Technology Pte. Ltd.

PEIJIA-B

4.900
-0.250-4.85%
Volume:396.00K
Turnover:1.98M
Market Cap:3.31B
PE:-13.75
High:5.155
Open:5.155
Low:4.900
Close:5.150
52wk High:7.890
52wk Low:3.730
Shares:675.00M
HK Float Shares:675.00M
Volume Ratio:0.70
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.356
ROE:-7.60%
ROA:-2.20%
PB:1.54
PE(LYR):-13.75
PS:3.62

Loading ...

Stock Track | PEIJIA-B Soars 7.75% Intraday on Strong Annual Results and Growth Prospects in TAVR and Neurointervention Segments

Stock Track
·
Apr 01

PEIJIA-B Shares Surge Over 7% in Afternoon Trading as Institutions Highlight TAVR Segment Benefits

Stock News
·
Apr 01

Daan Gene Subsidiary Secures Medical Device Registration Certificate

Stock News
·
Mar 31

Beijing Strong Biotechnologies' Subsidiary Secures Multiple Medical Device Registration Certificates

Stock News
·
Mar 31

Shinva Medical Subsidiary Obtains Class II Medical Device Registration Certificate

Stock News
·
Mar 31

PEIJIA-B Maintains Outperform Rating from CICC with HK$10 Price Target

Stock News
·
Mar 30

Press Release: Peijia Medical Announces 2025 Annual Results

Dow Jones
·
Mar 26

Peijia Medical Reports Robust 2025 Performance with Steady Growth in Core Operations

Stock News
·
Mar 26

Dingzhou Regulators Conduct Training on Medical Device Distribution Regulations

Deep News
·
Mar 26

Peijia Medical Chairman Plans Up to HK$15 Million Share Purchase

MT Newswires Live
·
Mar 26

Stock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase

Stock Track
·
Mar 26

BRIEF-Peijia Medical Says Increase In Shareholding By CEO

Reuters
·
Mar 26

Peijia Medical - Increase in Shareholding by CEO

THOMSON REUTERS
·
Mar 26

Peijia Medical; Chairman and CEO Yi Zhang increases stake via controlled corporation; transaction value capped at HKD 15 million

Reuters
·
Mar 26

BRIEF-Peijia Medical Says FY Loss And Total Comprehensive Expense Attributable Rmb203.3 Million

Reuters
·
Mar 25

PEIJIA-B Reports Fiscal Year Results: Revenue Up 15.82% to 713 Million Yuan, Neurointerventional Segment Profit Soars 86.6%

Stock News
·
Mar 25

Peijia Medical FY2025 segment profit for Neurointerventional Business jumps 86.6% to RMB97 million; revenue rises 15.8% to RMB713 million

Reuters
·
Mar 25

Peijia Medical FY2025; TaurusTrio TAV system wins NMPA approval for severe symptomatic aortic regurgitation; revenue rises 15.8% to CNY 713 million

Reuters
·
Mar 25

Peijia Medical FY Revenue RMB 712.9 Million

THOMSON REUTERS
·
Mar 25